Boston Scientific highlights benefits of CRT-Ds for women

Boston Scientific has published new clinical research which illustrates the efficacy of its cardiac resynchronisation therapy defibrillators (CRT-Ds) among female patients.

The medical technology firm conducted a trial involving more than 1,800 patients, which represents the world’s largest randomised CRT-D study to date.

It was found that, although the devices offered benefits to both genders, the women trialled experienced a 70 per cent reduction in heart failure events, compared to a 35 per cent rate among men.

Boston Scientific described the results as “significant” due to the fact that CRT-D therapy has traditionally been relatively underused among female patients.

Dr Kenneth Stein, chief medical officer at Boston Scientific’s cardiology, rhythm and vascular group, said: “Boston Scientific believes that all patients should have equal access to high-quality cardiovascular care regardless of gender.”

Earlier this month, the company launched its new Taxus Element coronary stent in Europe, after demonstrating its efficacy in clinical trials.